$MPLT earnings report

MapLight reports Q3 2026 net loss of $51.6 million, with $463.4 million in cash and ZEPHYR-2 Phase 3 planning underway. AlphAI read MapLight Therapeutics's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readMPLT · Q3 2026 · ended 2026-09-30

MapLight reports Q3 2026 net loss of $51.6 million, with $463.4 million in cash and ZEPHYR-2 Phase 3 planning underway

→Mixed quarter

The filing reports no revenue. Operating expenses rose sharply versus Q3 2025 (total operating expenses $55,343 thousand versus $31,498 thousand), and the company points to positive Phase 2 data and a runway through 2028. Two trial timelines appear inconsistently within the filing, and the company gives no numeric guidance.

EPS · GAAP
$(0.97)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses (Q3 2026)GAAP$44.21M––
General and administrative expenses (Q3 2026)GAAP$11.13M––
Total operating expenses (Q3 2026)GAAP$55.34M––
Loss from operations (Q3 2026)GAAP−$55.34M––
Interest income (Q3 2026)GAAP$3.09M––
Other income, net (Q3 2026)GAAP$633K––
Net loss (Q3 2026)GAAP−$51.62M––
Net loss per share, basic and diluted (Q3 2026)GAAP$(0.97)––
Research and development expenses (nine months ended Sep 30, 2026)GAAP$151.3M––
General and administrative expenses (nine months ended Sep 30, 2026)GAAP$32.07M––
Total operating expenses (nine months ended Sep 30, 2026)GAAP$183.4M––
Loss from operations (nine months ended Sep 30, 2026)GAAP−$183.4M––
Interest income (nine months ended Sep 30, 2026)GAAP$7.92M––
Other income, net (nine months ended Sep 30, 2026)GAAP$3.00M––
Net loss (nine months ended Sep 30, 2026)GAAP−$172.5M––
Net loss per share, basic and diluted (nine months ended Sep 30, 2026)GAAP$(3.60)––
Cash, cash equivalents and investments (as of Sep 30, 2026)other$463.4M––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The company completed a $150 million private placement in August 2026 with new and existing institutional investors, as previously announced. The company says proceeds are expected to primarily support ML-007C-MA, including the planned ZEPHYR-2 trial and the ongoing VISTA trial, as well as working capital and other general corporate purposes.

What drove it

  • The company attributes the R&D increase to the ongoing advancement of its product candidates and to higher employee-related expenses, including an increase in stock-based compensation expense of $5.8 million.
  • The company attributes the G&A increase to higher employee-related expenses, including an increase in stock-based compensation expense of $4.3 million, and to increases in professional fees and other expenses.
  • The company states it is pausing significant further investment in preclinical and discovery-stage programs beyond near-term milestones and foregoing their advancement into clinical development under the current operating plan.
  • Interest income rose from $1,549 thousand to $3,094 thousand in Q3 2026. The filing does not give a cause for this change.

Concerns

  • Net loss was $51,616 thousand in Q3 2026 against $29,418 thousand in Q3 2025, and $172,476 thousand for the nine months against $81,604 thousand. The filing reports no revenue line.
  • Total operating expenses for the nine months were $183,395 thousand against $85,706 thousand a year earlier. R&D alone was $151,328 thousand against $73,726 thousand.
  • Timelines are inconsistent within the filing. The headline states ZEPHYR-2 topline results are expected in the second half 2027, while the business update states topline results are expected in 2028. The headline states VISTA topline results are now expected in 2028, while the business update states they are expected in the second half of 2027. The filing does not reconcile these statements.
  • The filing describes VISTA topline timing as 'now expected' in 2028 but does not explain the reason for the change.
  • The ML-004 program has no set path. The company plans an End-of-Phase 2 meeting with the FDA, then intends to evaluate development options, including potential strategic collaborations and/or funding alternatives.
  • The weighted-average share count is printed as 53,100,322 for Q3 2026 against 791,127 for Q3 2025, and per-share losses are printed as $(0.97) against $(37.18). The filing does not explain these share figures.
  • Stockholders' equity fell from $458,372 thousand to $445,771 thousand between December 31, 2025 and September 30, 2026, while the filing reports a net loss of $172,476 thousand for the nine months.

What to watch

  • The FDA End-of-Phase 2 meeting for ML-007C-MA, and the registrational path it sets for ZEPHYR-2.
  • The VISTA topline timing, given the conflicting dates in the filing (second half 2027 in the business update, 2028 in the headline).
  • The outcome of the planned End-of-Phase 2 meeting for ML-004 and any strategic collaboration or funding alternatives the company pursues.
  • Quarterly operating expense trend, particularly R&D and G&A, against the $463.4 million cash balance and the company's statement that cash funds the program through 2028.
  • Whether the company provides cash flow figures or updated cash runway detail in its Form 10-Q, which the filing references for the quarter ended September 30, 2026.

Balance sheet and cash flow

  • Cash, cash equivalents and investments: $463,413 thousand as of September 30, 2026, compared with $453,096 thousand as of December 31, 2025.
  • Total assets: $477,183 thousand as of September 30, 2026, compared with $479,512 thousand as of December 31, 2025.
  • Total current liabilities: $30,902 thousand as of September 30, 2026, compared with $16,229 thousand as of December 31, 2025.
  • Total liabilities: $31,412 thousand as of September 30, 2026, compared with $21,140 thousand as of December 31, 2025.
  • Total stockholders' equity: $445,771 thousand as of September 30, 2026, compared with $458,372 thousand as of December 31, 2025.
  • The company expects existing cash, cash equivalents and investments to be sufficient to fund the continued advancement of ML-007C-MA through 2028, based on current operational plans and assumptions.
  • The filing does not report operating cash flow, investing cash flow, free cash flow or debt.

Analysis

MapLight reported a third quarter 2026 net loss of $(51,616) thousand, or $(0.97) per share, against a net loss of $(29,418) thousand, or $(37.18) per share, in the third quarter of 2025. Total operating expenses rose to $55,343 thousand from $31,498 thousand, led by R&D at $44,208 thousand against $27,094 thousand and G&A at $11,135 thousand against $4,404 thousand. The company attributes both increases in part to higher stock-based compensation, citing $5.8 million for R&D and $4.3 million for G&A. Interest income was $3,094 thousand against $1,549 thousand. The filing reports no revenue. The filing does not print prior-quarter (Q2 2026) figures, so this read compares only with the prior-year quarter.

For the nine months ended September 30, 2026, R&D was $151,328 thousand against $73,726 thousand and total operating expenses were $183,395 thousand against $85,706 thousand. The nine-month net loss was $(172,476) thousand against $(81,604) thousand. Expense growth is therefore concentrated in clinical development and in employee-related costs, as the company itself describes them.

The pipeline narrative centers on ML-007C-MA. The company reports a Phase 2 ZEPHYR trial in schizophrenia that met its primary endpoint, and it has started start-up activities for ZEPHYR-2, a planned Phase 3 trial, with an End-of-Phase 2 FDA meeting planned. The Alzheimer's disease psychosis program has Fast Track designation and an ongoing Phase 2 VISTA trial of approximately 300 participants. For ML-004 in autism, the company plans an End-of-Phase 2 meeting, after which it will evaluate options including collaborations and funding alternatives. The company also states it is pausing significant further investment in preclinical and discovery-stage programs beyond near-term milestones.

The balance sheet shows cash, cash equivalents and investments of $463,413 thousand at September 30, 2026, against $453,096 thousand at December 31, 2025. Total stockholders' equity fell to $445,771 thousand from $458,372 thousand over the same period. The company cites an August 2026 $150 million private placement and says the cash position is expected to fund ML-007C-MA through 2028. The filing does not report operating cash flow, so the cash consumption rate cannot be read from it directly.

Trial timing is stated inconsistently: the headline gives 2027 for ZEPHYR-2 and 2028 for VISTA, while the body gives 2028 for ZEPHYR-2 and second half 2027 for VISTA. Readers should confirm these dates with the company before relying on them.

Management, verbatim

We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.

Chris Kroeger, Co-Founder and Chief Executive Officer

With our cash position expected to fund operations through 2028, we are well-positioned to advance both programs while maintaining strategic and financial flexibility.

Chris Kroeger, Co-Founder and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-quarter (Q2 2026) figures for all income statement lines, because the filing prints only Q3 2026 and Q3 2025 for the quarter.
  • Year-over-year percentage changes for R&D, G&A, total operating expenses, net loss and EPS. The filing prints dollar amounts but no percentages.
  • Revenue, cost of sales and gross margin. The filing reports no revenue.
  • Operating cash flow, investing cash flow, free cash flow and cash burn for the quarter and nine months.
  • Prior-year cash balance at September 30, 2025, and a cash balance at June 30, 2026.
  • Net proceeds from the August 2026 private placement and the exact cash position after it.
  • Any numeric financial guidance, including operating expense or cash runway guidance beyond the statement that cash funds operations through 2028.
  • The reason for the change in VISTA topline timing to 2028, as stated in the headline.
  • The explanation for the difference between the ZEPHYR-2 and VISTA timing dates in the headline and the body of the filing.
  • Explanation of the change in weighted-average share count and per-share loss between periods.
  • Consensus estimates and share-price reaction, which are not part of this filing.
  • The previous outlook covered the period through the end of 2028 and non-numeric milestones only, which are not for the quarter reported here, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter 2026

AlphAI · Earnings readMPLT · Second quarter 2026 · ended June 30, 2026

MapLight reported positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia, continued enrollment in the Phase 2 VISTA ADP trial, and ended the quarter with $351.3 million in cash, cash equivalents and investments.

→Mixed quarter

The company reported positive ZEPHYR Phase 2 data and funding expected to support ML-007C-MA through the end of 2028, but quarterly net loss, R&D expense and G&A expense were higher than the prior-year period.

EPS · GAAP
$(1.32)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expensesGAAP$53.44M––
General and administrative expensesGAAP$10.11M––
Total operating expensesGAAP$63.55M––
Loss from operationsGAAP−$63.55M––
Interest incomeGAAP$2.35M––
Other income, netGAAP$1.01M––
Net lossGAAP−$60.19M––
Net loss per share - basic and dilutedGAAP$(1.32)––
Weighted-average number of common shares outstanding - basic and dilutedGAAP45,431,359––
Six-month research and development expensesGAAP$107.1M––
Six-month general and administrative expensesGAAP$20.93M––
Six-month total operating expensesGAAP$128.1M––
Six-month loss from operationsGAAP−$128.1M––
Six-month interest incomeGAAP$4.82M––
Six-month other income, netGAAP$2.37M––
Six-month net lossGAAP−$120.9M––
Six-month net loss per share - basic and dilutedGAAP$(2.66)––
Six-month weighted-average number of common shares outstanding - basic and dilutedGAAP45,354,488––
Cash, cash equivalents and investmentsother$351.3M––
Total assetsGAAP$368.3M––
Total current liabilitiesGAAP$19.29M––
Total liabilitiesGAAP$20.05M––
Total stockholders’ equityGAAP$348.3M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

through the end of 2028 outlook

  • NoteThe Company expects that its existing cash, cash equivalents and investments, together with the net proceeds from the recent private placement, will be sufficient to fund the continued advancement of ML-007C-MA through the end of 2028.
  • NoteTopline results from VISTA are expected in the second half of 2027.
  • NoteThe planned Phase 3 ZEPHYR-2 trial has topline results expected in 2028.
  • NoteThe Phase 2 VISTA trial is evaluating ML-007C-MA in approximately 300 participants with ADP.

What drove it

  • The Phase 2 ZEPHYR trial met its primary endpoint, with the 210/3 mg twice-daily dose demonstrating a statistically significant and clinically meaningful reduction in PANSS total score compared with placebo at Week 5.
  • ML-007C-MA demonstrated improvement on a prespecified cognitive-function endpoint in participants with baseline cognitive impairment and significant separation on CGI-S and the PANSS Marder positive factor.
  • R&D expenses increased primarily due to increases in clinical trial expenses and employee-related expenses, including an increase in stock-based compensation expense of $5.6 million.
  • G&A expenses increased primarily due to increases in employee-related expenses, including an increase in stock-based compensation expense of $2.9 million, and increases in professional fees and other expenses.
  • The Company is focusing resources on ML-007C-MA and is pausing further investment in preclinical and discovery-stage programs.

Concerns

  • The Phase 2 IRIS trial of ML-004 did not meet its primary endpoint in social communication.
  • The Company intends to evaluate the path forward for ML-004 following its planned End-of-Phase 2 discussion with the FDA, including potential strategic collaborations and/or funding alternatives.
  • Net loss was $(60,192) for the second quarter of 2026, compared with $(29,845) for the second quarter of 2025.
  • The planned Phase 3 ZEPHYR-2 trial has topline results expected in 2028, while VISTA topline results are expected in the second half of 2027.

What to watch

  • The Company’s End-of-Phase 2 meeting with the FDA regarding the registrational path for ML-007C-MA in schizophrenia and the planned Phase 3 ZEPHYR-2 trial.
  • Enrollment progress and topline results from the Phase 2 VISTA trial in the second half of 2027.
  • Topline results from the planned Phase 3 ZEPHYR-2 trial expected in 2028.
  • The path forward for ML-004 after the planned End-of-Phase 2 discussion with the FDA.
  • Execution of the $150 million private placement and the Company’s stated cash runway through the end of 2028.

Balance sheet and cash flow

  • Cash, cash equivalents and investments were $351.3 million as of June 30, 2026.
  • Cash, cash equivalents and investments were $351,341 as of June 30, 2026, compared with $453,096 as of December 31, 2025.
  • Total assets were $368,348 as of June 30, 2026, compared with $479,512 as of December 31, 2025.
  • Total current liabilities were $19,294 as of June 30, 2026, compared with $16,229 as of December 31, 2025.
  • Total liabilities were $20,049 as of June 30, 2026, compared with $21,140 as of December 31, 2025.
  • Total stockholders’ equity was $348,299 as of June 30, 2026, compared with $458,372 as of December 31, 2025.
  • In August 2026, the Company announced a $150 million private placement.

Analysis

MapLight’s quarter was defined by clinical execution rather than commercial results. The company reported that its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia met its primary endpoint, with the 210/3 mg twice-daily dose showing a statistically significant and clinically meaningful reduction in PANSS total score versus placebo at Week 5. The program also showed improvement on a prespecified cognitive-function endpoint among participants with baseline cognitive impairment and separation on CGI-S and the PANSS Marder positive factor. Management plans an End-of-Phase 2 FDA meeting to discuss the registrational path and the planned Phase 3 ZEPHYR-2 trial, with topline results expected in 2028.

The ADP program remains the nearer disclosed clinical catalyst. Enrollment continues in the Phase 2 VISTA trial, which is evaluating ML-007C-MA in approximately 300 participants with ADP, and topline results are expected in the second half of 2027. ML-007C-MA received Fast Track designation in December 2025 for hallucinations and delusions associated with ADP. In contrast, ML-004 in autism spectrum disorder did not meet its primary social-communication endpoint in the Phase 2 IRIS trial. The company highlighted a prespecified adolescent irritability subgroup result and plans to evaluate strategic collaborations and/or funding alternatives after an End-of-Phase 2 FDA discussion.

The financial statement shows increased spending to support development activities. Second-quarter R&D expense was $53,435, compared with $26,846 in the prior-year quarter, driven primarily by clinical trial expense and employee-related expense, including a $5.6 million increase in stock-based compensation expense. G&A expense was $10,113, compared with $3,817, reflecting employee-related expense, including a $2.9 million increase in stock-based compensation expense, as well as professional fees and other expenses. Total operating expenses were $63,548, and net loss was $(60,192), compared with $(29,845) in the prior-year quarter.

Liquidity and resource prioritization are central to the operating plan. Cash, cash equivalents and investments were $351.3 million as of June 30, 2026. The company also announced a $150 million private placement in August 2026 and stated that existing cash, cash equivalents and investments together with net PIPE proceeds are expected to fund continued advancement of ML-007C-MA through the end of 2028. Management is pausing further investment in preclinical and discovery-stage programs and will not advance those programs into clinical development under the current operating plan.

The principal figures to monitor are VISTA enrollment and the second-half 2027 readout, the FDA discussion and initiation path for ZEPHYR-2, and the company’s execution against its stated runway through the end of 2028. The quarter does not provide revenue, product segments, margins, operating cash flow, free cash flow, debt, or capital-return activity. No prior quarterly outlook was provided for comparison with reported results.

Management, verbatim

With positive Phase 2 data from ZEPHYR and continued progress in VISTA, we are focusing our efforts on advancing ML-007C-MA in both schizophrenia and ADP.

Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight

Together with our recent private placement and continued focus on capital discipline, we believe we are well positioned to execute on both programs through these key milestones.

Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight

Not in the filing

stated, not guessed
  • Total revenue
  • Revenue prior-year comparison
  • Revenue prior-quarter comparison
  • Revenue growth rates
  • Revenue segments
  • Gross profit
  • Gross margin
  • Operating income
  • GAAP net income
  • Non-GAAP metrics and reconciliations
  • Operating cash flow
  • Free cash flow
  • Debt
  • Share repurchases
  • Dividends
  • Prior-quarter income-statement metrics
  • Percentage changes for reported income-statement metrics
  • Prior outlook for comparison with actual results
  • Forward revenue guidance
  • Forward gross-margin guidance
  • Forward operating-expense guidance
  • Forward tax-rate guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about MPLT earnings dates

When is MapLight Therapeutics's next earnings date?
AlphAI has no date for MPLT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.